These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9989567)

  • 21. Placebo-controlled, double-blind study of the effects of proglumide in the treatment of schizophrenia.
    Whiteford HA; Stedman TJ; Welham J; Csernansky JG; Pond SM
    J Clin Psychopharmacol; 1992 Oct; 12(5):337-40. PubMed ID: 1362205
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of clozapine and adjunctive high-dose glycine in treatment-resistant schizophrenia.
    Potkin SG; Jin Y; Bunney BG; Costa J; Gulasekaram B
    Am J Psychiatry; 1999 Jan; 156(1):145-7. PubMed ID: 9892314
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Idazoxan, an alpha 2 antagonist, augments fluphenazine in schizophrenic patients: a pilot study.
    Litman RE; Hong WW; Weissman EM; Su TP; Potter WZ; Pickar D
    J Clin Psychopharmacol; 1993 Aug; 13(4):264-7. PubMed ID: 8104200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group.
    Zimbroff DL; Kane JM; Tamminga CA; Daniel DG; Mack RJ; Wozniak PJ; Sebree TB; Wallin BA; Kashkin KB
    Am J Psychiatry; 1997 Jun; 154(6):782-91. PubMed ID: 9167505
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical outcome following neuroleptic discontinuation in patients with remitted recent-onset schizophrenia.
    Gitlin M; Nuechterlein K; Subotnik KL; Ventura J; Mintz J; Fogelson DL; Bartzokis G; Aravagiri M
    Am J Psychiatry; 2001 Nov; 158(11):1835-42. PubMed ID: 11691689
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
    Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
    Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antipsychotic effect of cannabidiol.
    Zuardi AW; Morais SL; Guimarães FS; Mechoulam R
    J Clin Psychiatry; 1995 Oct; 56(10):485-6. PubMed ID: 7559378
    [No Abstract]   [Full Text] [Related]  

  • 28. Randomized, placebo-controlled study of ethyl-eicosapentaenoic acid as supplemental treatment in schizophrenia.
    Emsley R; Myburgh C; Oosthuizen P; van Rensburg SJ
    Am J Psychiatry; 2002 Sep; 159(9):1596-8. PubMed ID: 12202284
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A double-blind dose-reduction trial of fluphenazine decanoate for chronic, unstable schizophrenic patients.
    Inderbitzin LB; Lewine RR; Scheller-Gilkey G; Swofford CD; Egan GJ; Gloersen BA; Vidanagama BP; Waternaux C
    Am J Psychiatry; 1994 Dec; 151(12):1753-9. PubMed ID: 7977881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Detection of early warning signs in schizophrenic patients. Possible applications in prevention of recurrence].
    Wiedemann G; Hahlweg K; Hank G; Feinstein E; Müller U; Dose M
    Nervenarzt; 1994 Jul; 65(7):438-43. PubMed ID: 7800087
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G; Annable L; Campbell W
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Polypharmacy in the treatment of schizophrenic patients in three University Centers in the Federation of Bosnia and Herzegovina (F/BH).
    Loga-Zec S; Loga S
    Psychiatr Danub; 2011 Mar; 23(1):60-3. PubMed ID: 21448098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.
    Nakamura M; Ogasa M; Guarino J; Phillips D; Severs J; Cucchiaro J; Loebel A
    J Clin Psychiatry; 2009 Jun; 70(6):829-36. PubMed ID: 19497249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antipsychotic drug treatment in the prodromal phase of schizophrenia.
    Cannon TD; Huttunen MO; Dahlström M; Larmo I; Räsänen P; Juriloo A
    Am J Psychiatry; 2002 Jul; 159(7):1230-2. PubMed ID: 12091205
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clorazepate: double blind crossover comparison of a single nightly dose with diazepam thrice daily in anxiety.
    Magnus RV; Dean BC; Curry SH
    Dis Nerv Syst; 1977 Oct; 38(10):819-21. PubMed ID: 20284
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.
    Kane JM; Eerdekens M; Lindenmayer JP; Keith SJ; Lesem M; Karcher K
    Am J Psychiatry; 2003 Jun; 160(6):1125-32. PubMed ID: 12777271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 6-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia.
    Haas M; Unis AS; Armenteros J; Copenhaver MD; Quiroz JA; Kushner SF
    J Child Adolesc Psychopharmacol; 2009 Dec; 19(6):611-21. PubMed ID: 20035579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A controlled one-year study of pipotiazine palmitate and fluphenazine decanoate in chronic schizophrenic syndromes. Evaluation of results at 6 and 12 months' trial.
    Dencker SJ; Frankenberg K; Malm U; Zell B
    Acta Psychiatr Scand Suppl; 1973; 241():101-18. PubMed ID: 4147508
    [No Abstract]   [Full Text] [Related]  

  • 40. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
    Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
    JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.